Clinical Data Our other confirmatory study for eteplirsen 4658-301 also known is PROMOVI remains on schedule and is projected to be fully enrolled by the end of 2015 in the first quarter of 2016.FDA has stressed that any accelerated approval would require confirmatory studies to verify the clinical benefit and that confirmatory studies should be underway at the time of approval.